Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Extracellular CIRP induces macrophage endotoxin tolerance through IL-6R–mediated STAT3 activation
Mian Zhou, … , Gaifeng Ma, Ping Wang
Mian Zhou, … , Gaifeng Ma, Ping Wang
Published February 6, 2020
Citation Information: JCI Insight. 2020;5(5):e133715. https://doi.org/10.1172/jci.insight.133715.
View: Text | PDF
Research Article Immunology Inflammation

Extracellular CIRP induces macrophage endotoxin tolerance through IL-6R–mediated STAT3 activation

  • Text
  • PDF
Abstract

Extracellular cold-inducible RNA-binding protein (eCIRP) is a damage-associated molecular pattern, whose effect on macrophages is not entirely elucidated. Here we identified that eCIRP promotes macrophage endotoxin tolerance. Septic mice had higher serum levels of eCIRP; this was associated with a reduced ex vivo immune response of their splenocytes to LPS. Pretreatment of macrophages with recombinant murine CIRP (rmCIRP) resulted in a tolerance to LPS stimulation as demonstrated by a reduction of TNF-α production. We found that eCIRP increased phosphorylated STAT3 (p-STAT3) in macrophages. A STAT3 inhibitor, Stattic, rescued macrophages from rmCIRP-induced tolerance by restoring the release of TNF-α in response to LPS stimulation. We discovered strong binding affinity between eCIRP and IL-6 receptor (IL-6R) as revealed by Biacore, fluorescence resonance energy transfer (FRET), and their colocalization in macrophages by immunostaining assays. Blockade of IL-6R with its neutralizing Ab inhibited eCIRP-induced p-STAT3 and restored LPS-stimulated TNF-α release in macrophages. Incubation of macrophages with rmCIRP skewed them toward an M2 phenotype, while treatment with anti–IL-6R Ab prevented rmCIRP-induced M2 polarization. Thus, we have demonstrated that eCIRP activates p-STAT3 via a novel receptor, IL-6R, to promote macrophage endotoxin tolerance. Targeting eCIRP appears to be a new therapeutic option to correct immune tolerance in sepsis.

Authors

Mian Zhou, Monowar Aziz, Naomi-Liza Denning, Hao-Ting Yen, Gaifeng Ma, Ping Wang

×

Figure 3

Inhibition of STAT3 by Stattic rescues macrophages from eCIRP-induced endotoxin tolerance.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of STAT3 by Stattic rescues macrophages from eCIRP-induced en...
RAW264.7 cells (5 × 105/mL) were pretreated with PBS or rmCIRP (1 μg/mL) in the absence or presence of Stattic (3 μM) for 24 hours. Cells were then washed with medium to remove rmCIRP in the supernatants, and they were further stimulated with LPS (10 ng/mL). After 5 hours, culture supernatants were collected and assessed for (A) TNF-α and (B) IL-6. Data are expressed as mean ± SEM (n = 7 samples/group). The experiments were performed 3 times, and all data were used for analysis. The groups were compared by 1-way ANOVA and SNK method. *P < 0.05 vs. pre-rmCIRP (–), LPS (–); #P < 0.05 vs. pre-rmCIRP (–), LPS (+); †P < 0.05 vs. pre-rmCIRP (+), LPS (+).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts